Incannex Development Update for IHL-42X for Obstructive Sleep Apnoea (‘OSA’)
Incannex Healthcare Inc. (IXHL)
Company Research
Source: GlobeNewswire
Highlights: Incannex has engaged CMAX Clinical Research and Novotech CRO to undertake a bioavailability/bioequivalence (‘BA/BE’) study to assess the pharmacokinetics and tolerability of IHL-42X in 116 participantsIncannex is well progressed in drafting an Investigational New Drug (‘IND’) Application for submission to the US Food and Drug Administration (‘FDA’) in Q1 of 2023Once the IND is open, Incannex will commence pivotal, multi-site Phase 2/3 clinical trials investigating the effects of IHL-42X in patients with OSA over a 12-month periodPhase 2/3 pivotal trials will include between 20 to 30 trial sites, including many in the United States. Sixty-three clinical trial sites have expressed interest in conducting the trial. MELBOURNE, Australia, Nov. 17, 2022 (GLOBE NEWSWIRE) -- Incannex Healthcare Limited (Nasdaq: IXHL) (ASX: IHL), (‘Incannex’ or the ‘Company’) a clinical-stage pharmaceutical company developing unique medicinal cannabinoid pharmaceutical products and psychedelic
Show less
Read more
Impact Snapshot
Event Time:
IXHL
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
IXHL alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
IXHL alerts
High impacting Incannex Healthcare Inc. news events
Weekly update
A roundup of the hottest topics
IXHL
News
- Incannex Healthcare Inc. Quarterly Update, Q1 2024GlobeNewswire
- CNDB and SOND among mid-day movers [Seeking Alpha]Seeking Alpha
- Incannex Announces Positive Topline Results from Phase 2 Psi-GAD1 Clinical Trial of Psilocybin in Generalised Anxiety DisorderGlobeNewswire
- Incannex Completes Successful Pre-IND Meeting with the FDA for CannQuit-N; a Novel Solution for Tobacco Smoking CessationGlobeNewswire
- We're Keeping An Eye On Incannex Healthcare's (NASDAQ:IXHL) Cash Burn Rate [Yahoo! Finance]Yahoo! Finance
IXHL
Sec Filings
- 4/16/24 - Form 8-K
- 3/5/24 - Form 8-K
- 2/28/24 - Form 8-K
- IXHL's page on the SEC website